Neurotensin: peptide for the next millennium

Pothoulakis, 1998, Neuroimmune mechanisms of intestinal response to stress: role of corticotropin-releasing factor and neurotensin, Ann NY Acad Sci, 840, 635, 10.1111/j.1749-6632.1998.tb09602.x

Bissette, 1976, Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin, Nature, 262, 607, 10.1038/262607a0

Bissette, 1978, Modification of pentobarbital-induced sedation by natural and synthetic peptides, Neuropharmacology, 17, 229, 10.1016/0028-3908(78)90106-5

Elliott, 1986, Repeated neurotensin administration in the ventral tegmental area: effects on baseline and d-amphetamine-induced locomotor activity, Neurosci Lett, 68, 239, 10.1016/0304-3940(86)90149-7

Kasckow, 1991, The neurobiology of neurotensin: focus on neurotensin-dopamine interactions, Regul Pept, 36, 153, 10.1016/0167-0115(91)90053-J

Clineschmidt, 1979, Neurotensin: antinocisponsive action in rodents, Eur J Pharmacol, 54, 129, 10.1016/0014-2999(79)90415-1

Al-Rodhan, 1991, Structure–antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem, Brain Res, 557, 227, 10.1016/0006-8993(91)90139-M

Kinkead, 1999, Does neurotensin mediate the effects of antipsychotic drugs?, Soc Biol Psych, 46, 340, 10.1016/S0006-3223(99)00070-0

Uhl, 1977, Neurotensin, a central nervous system peptide: apparent receptor binding in brain membranes, Brain Res, 130, 299, 10.1016/0006-8993(77)90277-3

Vincent, 1995, Neurotensin receptors: binding properties, transduction pathways, and structure, Mol Neurobiol, 15, 501, 10.1007/BF02071313

Vincent, 1999, Neurotensin and neurotensin receptors, Trends Pharmacol Sci, 20, 302, 10.1016/S0165-6147(99)01357-7

Hermans, 1998, Mechanisms of regulation of neurotensin receptors, Pharmacol Ther, 79, 89, 10.1016/S0163-7258(98)00009-6

Goedert, 1984, Specific binding of tritiated neurotensin to rat brain membranes: characterization and regional distribution, Brain Res, 304, 71, 10.1016/0006-8993(84)90862-X

Kanba, 1988, [3H]neurotensin(8–13) binds in human brain to the same sites as does [3H]neurotensin but with higher affinity, J Neurochem, 50, 131, 10.1111/j.1471-4159.1988.tb13239.x

Moyse, 1987, Distribution of neurotensin binding sites in rat brain: a light microscopic radioautographic study using monoiodo [125I]Tyr3-neurotensin, Neuroscience, 22, 525, 10.1016/0306-4522(87)90350-2

Tanaka, 1990, Structure and functional expression of the cloned rat neurotensin receptor, Neuron, 4, 847, 10.1016/0896-6273(90)90137-5

Vita, 1993, Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor, FEBS Lett, 317, 139, 10.1016/0014-5793(93)81509-X

Watson, 1993, Identification of a polymorphism in the human neurotensin receptor gene, Mayo Clin Proc, 68, 1043, 10.1016/S0025-6196(12)60896-9

Le, 1997, Characterization of the genomic structure, promoter region, and a tetranucleotide repeat polymorphism of the human neurotensin receptor gene, J Biol Chem, 272, 1315, 10.1074/jbc.272.2.1315

Chalon, 1996, Molecular cloning of a levocabastine-sensitive neurotensin binding site, FEBS Lett, 386, 91, 10.1016/0014-5793(96)00397-3

Mazella, 1996, Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain, J Neurosci, 16, 5613, 10.1523/JNEUROSCI.16-18-05613.1996

Vita, 1998, Molecular cloning and characterization of a new human neurotensin binding site that recognizes levocabastine, Eur J Pharmacol, 360, 265, 10.1016/S0014-2999(98)00678-5

Mazella, 1988, Solubilization and characterization of active neurotensin receptors from mouse brain, J Biol Chem, 263, 144, 10.1016/S0021-9258(19)57370-7

Labbe-Jullie, 1994, In vivo and in vitro structure–activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes, J Pharmacol Exp Ther, 268, 328

Gilbert, 1989, Neurotensin(8–13): comparison of novel analogs for stimulation of cyclic GMP formation in neuroblastoma clone N1E-115 and receptor binding to human brain and intact N1E-115 cells, Biochem Pharmacol, 38, 3377, 10.1016/0006-2952(89)90637-0

Cusack, 1995, Pharmacological and biochemical profiles of unique neurotensin 8–13 analogs exhibiting species selectivity, stereoselectivity, and superagonism, J Biol Chem, 270, 18359, 10.1074/jbc.270.31.18359

Tyler, 1998, Evidence for additional neurotensin receptor subtypes: neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception, Brain Res, 792, 246, 10.1016/S0006-8993(98)00150-4

Pang, 1996, Proposed ligand binding site of the transmembrane receptor for neurotensin(8–13), J Biol Chem, 271, 15060, 10.1074/jbc.271.25.15060

Checler, 1986, Purification and characterization of a novel neurotensin-degrading peptidase from rat brain synaptic membranes, J Biol Chem, 261, 11274, 10.1016/S0021-9258(18)67379-X

Lundquist, 1999, Preparation and receptor binding affinities of cyclic C-terminal neurotensin 8–13 and 9–13 analogues, Bioorgan Med Chem Lett, 9, 2579, 10.1016/S0960-894X(99)00420-5

Lundquist, 2000, Synthesis of neurotensin 9–13 analogues exhibit enhanced human neurotensin receptor binding affinities, Bioorg Med Chem Lett, 10, 453, 10.1016/S0960-894X(00)00018-4

Pardridge, 1998, CNS drug design based on principles of blood–brain barrier transport, J Neurochem, 70, 1781, 10.1046/j.1471-4159.1998.70051781.x

Machida, 1993, Pharmacokinetics of novel hexapeptides with neurotensin activity in rats, Biol Pharm Bull, 16, 43, 10.1248/bpb.16.43

Deniker, 1970

Tyler, 1999, In vitro binding and CNS effects of novel neurotensin agonists that cross the blood brain barrier, Neuropharmacology, 38, 1027, 10.1016/S0028-3908(99)00011-8

Fauq, 1998, Synthesis of (2S)-2-amino-3-(1H-4-indolyl) propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides, Tetrahedron: Asymmetry, 9, 4127, 10.1016/S0957-4166(98)00445-5

Jolicoeur, 1981, Differential neurobehavioral effects of neurotensin and structural analogues, Peptides, 2, 171, 10.1016/S0196-9781(81)80031-9

Cusack, 2000, Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol, Brain Res, 856, 48, 10.1016/S0006-8993(99)02363-X

Boules, 2000, A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents, Brain Research, 865, 35, 10.1016/S0006-8993(00)02187-9

Bentancur, 1997, Nonpeptide antagonists of neuropeptide receptors: tools for research and therapy, Trends Pharmacol Sci, 18, 372, 10.1016/S0165-6147(97)90666-0

Dubuc, 1994, The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes, Br J Pharmacol, 112, 352, 10.1111/j.1476-5381.1994.tb13077.x

Labbe-Jullie, 1996, [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor, Mol Pharm, 47, 1050

Gully, 1993, Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor, Proc Natl Acad Sci USA, 90, 65, 10.1073/pnas.90.1.65

Pugsley, 1994, Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists, Peptides, 16, 37, 10.1016/0196-9781(94)00146-W

Poncelet, 1994, Turning behavior induced by intrastriatal injection of neurotensin in mice: sensitivity to non-peptide neurotensin antagonists, Naunyn-Schmiedeberg’s Arch Pharmacol, 349, 57, 10.1007/BF00178206

Smith, 1997, Dose dependent pain-facilitatory and -inhibitory actions of neurotensin are revealed by SR 48692, a nonpeptide neurotensin antagonist: influence on the antinociceptive effect of morphine, J Pharmacol Exp Ther, 282, 899

Steinberg, 1994, SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission, Neuroscience, 59, 921, 10.1016/0306-4522(94)90295-X

Gully, 1997, Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist, J Pharmacol Exp Ther, 280, 802

Bentacur, 1998, Characterization of a new neurotensin receptor antagonist, SR 142948A, in rat brain, Eur J Pharmacol, 343, 67, 10.1016/S0014-2999(97)01510-0

Heaulme, 1997, Involvement of potentially distinct neurotensin receptors in neurotensin-induced stimulation of striatal dopamine release evoked by KCl versus electrical depolarization, Neuropharmacology, 36, 1447, 10.1016/S0028-3908(97)00131-7

Akhtar, 1997, In vivo studies with antisense oligonucleotides, Trends in Pharmacological Sciences, 18, 12, 10.1016/S0165-6147(96)01002-4

Tyler, 1998, Specific gene blockade shows that peptide nucleic acids readily enter neuronal cells in vivo, FEBS Lett, 421, 208, 10.1016/S0014-5793(97)01575-5

Tyler, 1999, Peptide nucleic acids targeted to the neurotensin receptor and administered intraperitoneally cross the blood brain barrier and specifically reduce gene expression, Proc Natl Acad Sci, 96, 7053, 10.1073/pnas.96.12.7053

Dubuc, 1999, Identification of the receptor subtype involved in the analgesic effect of neurotensin, J Neurosci, 19, 503, 10.1523/JNEUROSCI.19-01-00503.1999

Quirion, 1992, Distribution of neurotensin receptors in mammalian brain, Ann NY Acad Sci, 668, 109, 10.1111/j.1749-6632.1992.tb27343.x

Drumheller, 1990, Effects of neurotensin on regional brain concentrations of dopamine, serotonin and their main metabolites, Neuropeptides, 15, 169, 10.1016/0143-4179(90)90150-W

Euler, 1990, Intraventricular injection of neurotensin reduces dopamine D2 agonist binding in rat forebrain and intermediate lobe of the pituitary gland. Relationship to serum hormone levels and nerve terminal coexistence, Brain Res, 531, 253, 10.1016/0006-8993(90)90781-6

Myers, 1986, CCK and other peptides modulate hypothalamic norepinephrine release in the rat: dependance on hunger or satiety, Brain Res Bull, 17, 583, 10.1016/0361-9230(86)90229-7

Nemeroff, 1982, Interactions of neurotensin with brain dopamine systems, Ann NY Acad Sci, 400, 330, 10.1111/j.1749-6632.1982.tb31579.x

Kinkead, 1994, The effects of typical and atypical antipsychotic drugs on neurotensin-containing neurons in the central nervous system, J Clin Psychiatry, 55, 30

Rostene, 1997, Use of nonpeptide antagonists to explore the physiological roles of neurotensin. Focus on brain neurotensin/dopamine interactions, Ann NY Acad Sci, 814, 125, 10.1111/j.1749-6632.1997.tb46151.x

Palacios, 1981, Neurotensin receptors are located on dopamine-containing neurons in rat midbrain, Nature, 294, 587, 10.1038/294587a0

Yamada, 1994, Deletion mutation in the putative third intracellular loop of the rat neurotensin receptor abolishes polyphosphoinositide hydrolysis but not cyclic AMP formation in CHO-K1 cells, Mol Pharmacol, 46, 470

Nemeroff, 1986, The interaction of neurotensin with dopaminergic pathways in the central nervous system: basic neurobiology and implications for the pathogenesis and treatment of schizophrenia, Psychoneuroendocrinology, 11, 15, 10.1016/0306-4530(86)90029-6

Kitabji, 1989, Neurotensin modulates dopamine neurotransmission at several levels along brain dopaminergic pathways, Neurochem Int, 14, 111, 10.1016/0197-0186(89)90110-1

Garver, 1991, Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients, Am J Psychiatry, 148, 484, 10.1176/ajp.148.4.484

Rostene, 1992, Interaction between neurotensin and dopamine in the brain: morphological and clinical evidence, Ann NY Acad Sci, 668, 217, 10.1111/j.1749-6632.1992.tb27352.x

Lambert, 1995, Anatomy and mechanisms of the neurotensin-dopamine interactions in the central nervous system, Ann NY Acad Sci, 757, 377, 10.1111/j.1749-6632.1995.tb17496.x

Govoni, 1980, Increase of neurotensin content elicited by neuroleptics in nucleus accumbens, J Pharmacol Exp Ther, 215, 413

Kilts, 1988, Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei, Biochem Pharmacol, 37, 1547, 10.1016/0006-2952(88)90017-2

Merchant, 1992, Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum, J Neurosci, 12, 652, 10.1523/JNEUROSCI.12-02-00652.1992

Uhl, 1984, Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substania nigra, Nature, 309, 350, 10.1038/309350a0

Bolden-Watson, 1993, Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra, J Neurochem, 61, 1141, 10.1111/j.1471-4159.1993.tb03631.x

Radke, 1998, Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions, Proc Natl Acad Sci, 95, 11462, 10.1073/pnas.95.19.11462

Nemeroff, 1992, Neurotensin, antipsychotic drugs, and schizophrenia. Basic and clinical studies, Ann NY Acad Sci, 668, 146, 10.1111/j.1749-6632.1992.tb27346.x

Ervin, 1981, Neurotensin blocks certain amphetamine-induced behaviors, Nature, 291, 73, 10.1038/291073a0

Jolicoeur, 1985, The effects of neurotensin and d-tyr1 1-NT on the hyperactivity induced by intra-accumbens administration of a potent dopamine receptor agonist, Neuropeptides, 6, 143, 10.1016/0143-4179(85)90105-2

Wagstaff, 1996, Dopamine D-2 receptors regulate neurotensin release from nucleus accumbens and striatum as measured by in vivo microdialysis, Brain Res, 721, 196, 10.1016/0006-8993(96)00132-1

Adams, 1997, Loss of haloperidol induced gene expression and catalepsy in protein kinase A-deficient mice, Proc Natl Acad Sci USA, 94, 12157, 10.1073/pnas.94.22.12157

Sarhan, 1997, Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist, Peptides, 18, 1223, 10.1016/S0196-9781(97)00145-9

Jolicoeur, 1993, Atypical neuroleptic-like behavioral effects of neurotensin, Brain Res Bull, 32, 487, 10.1016/0361-9230(93)90295-M

Jolicoeur, 1991, Neurotensin selectively antagonizes apomorphine-induced stereotyped climbing, Pharmacol Biochem Behav, 38, 463, 10.1016/0091-3057(91)90307-N

Nemeroff, 1977, Neurotensin: central nervous system effects of a hypothalamic peptide, Brain Res, 128, 485, 10.1016/0006-8993(77)90173-1

Luttinger, 1981, Enhancement of ethanol-induced sedation and hypothermia by centrally administered neurotensin, B-endorphin and bombesin, Neuropharmacology, 20, 305, 10.1016/0028-3908(81)90139-8

Nemeroff, 1979, Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine, Proc Natl Acad Sci USA, 76, 5368, 10.1073/pnas.76.10.5368

Nemeroff, 1983, Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies, J Pharmacol Exp Ther, 225, 337

Luttinger, 1982, PAJ. The effects of neuropeptides on discrete trial-conditioned avoidance responding, Brain Res, 237, 183, 10.1016/0006-8993(82)90566-2

Nemeroff, 1980, Neurotensin: perchance an endogenous neuroleptic?, Biol Psychiatry, 15, 283

Wolf, 1995, Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects, J Neural Trans, 102, 55, 10.1007/BF01276565

Lahti, 1998, [3H]Neurotensin receptor densities in human postmortem brain tissue obtained from normal and schizophrenic persons. An autoradiographic study, J Neural Trans, 105, 507, 10.1007/s007020050074

Widerlov, 1982, Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment, Am J Psychiatry, 139, 1122, 10.1176/ajp.139.9.1122

Lindstrom, 1988, Reduced CSF neurotensin concentration in drug-free schizophrenia patients, Schizophr Res, 1, 55, 10.1016/0920-9964(88)90040-0

Nemeroff, 1989, Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulemia and premenstrual syndrome, J Neuropsychiatry Clin Neurosci, 1, 16, 10.1176/jnp.1.1.16

Sharma, 1997, CSF neurotensin concentrations and antipsychotic treatment in schizophrenic and schizoaffective disorder, Am J Psychiatry, 154, 1019, 10.1176/ajp.154.7.1019

Breslin, 1994, CSF concentration of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates, Schizophr Res, 12, 35, 10.1016/0920-9964(94)90082-5

Rowe, 1992, Central administration of neurotensin stimulates hypothalamic-pituitary-adrenal activity, Ann NY Acad Sci, 668, 365, 10.1111/j.1749-6632.1992.tb27378.x

Nicot, 1994, Blockade of neurotensin binding in the rat hypothalamus and of the central action of neurotensin on the hypothalamic-pituitary-adrenal axis with non-peptide receptor antagonists, Neuroendocrinology, 59, 572, 10.1159/000126707

Sheppard, 1983, The effect of thyroid hormones in vitro and in vivo on hypothalamic neurotensin release and content, Endocrinology, 112, 1996, 10.1210/endo-112-6-1996

Malendowick, 1990, Effects of prolonged administration of neurotensin, arginine-vasopressin, NPY, and bombesin on blood TSH, T3, and T4 levels in the rat, In Vivo, 4, 259

Fuxe, 1984, Studies on the neurotensin-catecholamine interactions in the hypothalamus and in the forebrain of the male rat, Neurochem Int, 6, 737, 10.1016/0197-0186(84)90005-6

Wolfe, 1978, Increased glucose production following neurotensin administration, Life Sci, 22, 1043, 10.1016/0024-3205(78)90273-4

Gudelsky, 1989, Neurotensin activates tuberoinfundibular dopamine neurons and increases serum corticosterone concentrations in the rat, Neuroendocrinology, 49, 604, 10.1159/000125176

McCann, 1982, The effects of neurotensin on anterior pituitary hormone secretion, Ann NY Acad Sci, 400, 160, 10.1111/j.1749-6632.1982.tb31567.x

Tyler-McMahon, 2000, A highly potent neurotensin analog that crosses the blood brain barrier and causes hypothermia and antinociception, Eur J Pharm, 390, 107, 10.1016/S0014-2999(99)00877-8

Schaeffer, 1998, SR142948A is a potent antagonist of the cardiovascular effects of neurotensin, J Cardiovasc Pharmacol, 31, 545, 10.1097/00005344-199804000-00012

Nemeroff, 1980, Neurotensin-induced hypothermia: evidence for an interaction with dopaminergic systems and the hypothalamic-pituitary-thyroid axis, Brain Res, 195, 69, 10.1016/0006-8993(80)90867-7

Kalivas, 1982, Neuroanatomical site specific modulation of spontaneous motor activity by neurotensin, Eur J Pharmacol, 78, 471, 10.1016/0014-2999(82)90491-5

McCann, 1992, Control of anterior pituitary hormone secretion by neurotensin, Ann NY Acad Sci, 668, 287, 10.1111/j.1749-6632.1992.tb27357.x